Background Most guidelines recommend either a long-acting beta-agonist (LABA) plus an
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …

Background We evaluated the effect of dual, longacting inhaled bronchodilator treatment on
exacerbations in patients with severe and very severe chronic obstructive pulmonary …

We investigated the efficacy and safety of dual bronchodilation with QVA149 versus its
monocomponents indacaterol and glycopyrronium, tiotropium and placebo in patients with …

Background QVA149 is an inhaled fixed-dose combination therapy under development for
the treatment of chronic obstructive pulmonary disease (COPD). It combines indacaterol (a …

NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA)
in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium …

Background NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic
antagonist glycopyrronium bromide in development for the treatment of chronic obstructive …

Rationale: There are no studies on withdrawal of inhaled corticosteroids in patients on long-term
triple therapy in the absence of frequent exacerbations. Objectives: To evaluate the …

We evaluated the effect of QVA149, a dual bronchodilator combining indacaterol and
glycopyrronium, on direct patient-reported dyspnoea in patients with moderate-to-severe chronic …

Background The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment
strategy recommends the use of one or more bronchodilators according to the patient’s …

Rationale: Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy
recommends the combination of two long-acting bronchodilators of different pharmacologic …